Mixed results for etrolizumab in UC trial program

Etrolizumab, an investigational drug developed by Genentech, failed to meet the primary maintenance endpoints in several phase 3 trials and had mixed results in other induction studies, according to a company press release.Researchers evaluated the drug, a dual anti-integrin that inhibits alpha4beta7 and alphaEbeta7, in a trial program comprising eight randomized-controlled trials, as well as two open-label extension and safety monitoring studies.In the studies that explored the drug’s efficacy in inducing remission in patients with moderate to severe ulcerative colitis, etrolizumab metRead More